- Home
- » Tags
- » Deferasirox
Top View
- Iron Chelating Agents (Desferal Exjade Ferriprox Jadenu) C15214-A
- WHO Drug Information Vol
- Lists of Medicinal Products for Rare Diseases in Europe*
- Exjade (Deferasirox) Tablets Label
- An Open-Label, Phase II, Randomized, Pilot Study to Assess the Effect In
- Neonatal Murine Engineered Cardiac Tissue Toxicology Model Impact Of
- Wo 2010/099542 A2
- Chelation Therapy Hs-092
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Exjade, INN-Deferasirox
- Is Ferroptosis Involved in ROS-Induced Testicular Lesions in a Varicocele Rat Model? Erfaneh Shaygannia1, Mohammad H
- Formulation Development and Evaluation of Deferasirox Dispersible Tablets
- Use of Chelating Agents in Medicine
- Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
- Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-Based Case Report
- The Cardioprotective Effect of Dexrazoxane (Cardioxane) Is Consistent with Sequestration of Poly(ADP-Ribose) by Self-Assembly and Not Depletion of Topoisomerase 2B
- Iron Chelators
- 5.01.613 Oral Iron Chelating Agents
- Parenteral Iron
- Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
- Deferasirox, an Iron-Chelating Agent, Improves Testicular Morphometric and Sperm Functional Parameters in a Rat Model of Varicocele
- EXJADE / JADENU (Deferasirox) RATIONALE for INCLUSION IN
- Reimbursement Criteria for Frequently Requested Drugs
- Chelation in Metal Intoxication
- Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication
- Chelation Agents Policy #: Rx.01.22
- EXJADE General
- Assessment Report Exjade (Deferasirox)
- Pdf 578.32 K
- Exjade. INN: Deferasirox
- Synergistic Inhibition of Tumor Cell Proliferation by Metformin and Mito-Metformin in the Presence of Iron Chelators
- Jadenu® (Deferasirox)
- Chelating Agents Pa Summary
- Chelation for Autism Spectrum Disorder (ASD) (Review)
- Iron Chelators in Reducing Serum Ferritin Level in Thalassemia Major: a Randomized Trial
- Formulation of Deferasirox Into Dispersible Tablet for the Treatment of Chronic Iron Overload
- (12) United States Patent (10) Patent No.: US 8,993,606 B2 Rienhoff, Jr
- TIF 2021 Guidelines for the Management of Transfusion
- Protein Carbonylation in Patients with Myelodysplastic Syndrome: an Opportunity for Deferasirox Therapy
- List Item Deferasirox Mylan : EPAR
- Monitoring Deferasirox Therapy Ashutosh Lal, MD, UCSF Benioff Childrenʼs Hospital Oakland CHECKLISTS
- View U.S. Patent Application Publication No. US-2020-0199185 in PDF Format
- JADENU Known Hypersensitivity to Deferasirox Or Any Component of JADENU
- Influence of Single-Nucleotide Polymorphisms on Deferasirox
- BMC Medical Genomics Biomed Central
- Deferasirox-Induced Iron Depletion Promotes Bclxl Downregulation
- Safety, Tolerability, and Pharmacokinetics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Transfusional Iron Overload
- Iron and Copper Intracellular Chelation As an Anticancer Drug Strategy
- Efficacy and Safety of Iron-Chelation Therapy With